Roche's Experimental Obesity Drug CT-388 Shows Significant Weight Loss in Early Trials

Patients experienced an average weight reduction of 18.8% over 24 weeks, positioning Roche as a strong contender in the competitive weight loss market.

All patients treated with CT-388 lost at least 5% of their weight, with 45% losing over 20%.
The drug mimics gut hormones GLP-1 and GIP to suppress appetite and control blood sugar.
Mild to moderate gastrointestinal side effects were the most common adverse events reported.
Roche's stock rose by 4% following the announcement of the trial results.
The company aims to develop CT-388 for both obesity and type 2 diabetes treatment.